Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
—
−0.22HKD
−521.04 MHKD
371.52 MHKD
2.29 B
About MICROPORT CARDIOFLOW MEDTECH CORP
Sector
Industry
Headquarters
Shanghai
Website
Employees (FY)
592
Founded
2019
FIGI
BBG00Y4744W7
GNI Group Ltd. is a Japan-based company engaged in the drug discovery activities that utilize biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The Company researches and develops therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 2160 is 1.04 HKD — it has increased by 0.97% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange MICROPORT CARDIOFLOW MEDTECH CORP stocks are traded under the ticker 2160.
MICROPORT CARDIOFLOW MEDTECH CORP is going to release the next earnings report on Aug 27, 2024. Keep track of upcoming events with our Earnings Calendar.
2160 stock is 6.73% volatile and has beta coefficient of 1.33. Check out the list of the most volatile stocks — is MICROPORT CARDIOFLOW MEDTECH CORP there?
Yes, you can track MICROPORT CARDIOFLOW MEDTECH CORP financials in yearly and quarterly reports right on TradingView.
2160 stock has risen by 10.64% compared to the previous week, the month change is a 2.80% fall, over the last year MICROPORT CARDIOFLOW MEDTECH CORP has showed a 55.17% decrease.
2160 net income for the last quarter is −315.60 M HKD, while the quarter before that showed −202.90 M HKD of net income which accounts for −55.55% change. Track more MICROPORT CARDIOFLOW MEDTECH CORP financial stats to get the full picture.
Today MICROPORT CARDIOFLOW MEDTECH CORP has the market capitalization of 2.48 B, it has increased by 1.09% over the last week.
No, 2160 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 2160 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MICROPORT CARDIOFLOW MEDTECH CORP stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 29, 2024, the company has 592.00 employees. See our rating of the largest employees — is MICROPORT CARDIOFLOW MEDTECH CORP on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MICROPORT CARDIOFLOW MEDTECH CORP technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MICROPORT CARDIOFLOW MEDTECH CORP stock shows the sell signal. See more of MICROPORT CARDIOFLOW MEDTECH CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MICROPORT CARDIOFLOW MEDTECH CORP future price: according to them, 2160 price has a max estimate of 2.20 HKD and a min estimate of 1.15 HKD. Read a more detailed MICROPORT CARDIOFLOW MEDTECH CORP forecast: see what analysts think of MICROPORT CARDIOFLOW MEDTECH CORP and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MICROPORT CARDIOFLOW MEDTECH CORP EBITDA is −248.93 M HKD, and current EBITDA margin is −67.52%. See more stats in MICROPORT CARDIOFLOW MEDTECH CORP financial statements.